MedCap AB (SE:MCAP)
:MCAP
Top Page
MedCap AB
(MCAP)
Select Model
Select Model
Rating:64Neutral
Price Target:
kr508.00
▼(-4.69% Downside)
Action:ReiteratedDate:02/08/26
The score is primarily supported by solid financial performance driven by strong revenue growth and steady operating profitability, but is held back by higher 2025 leverage, weaker earnings-quality signals from uneven cash conversion, mixed technical momentum, and a high P/E valuation with no dividend yield provided.
Positive Factors
Sustained Revenue Growth
Multi-year top-line expansion from ~0.8B to ~2.1B demonstrates durable commercial scaling across subsidiaries. Persistent revenue growth supports operational leverage, broadens product/customer reach in healthcare niches, and enhances the company’s capacity to fund reinvestment and value-creating M&A.
Negative Factors
Rising Leverage
A material step-up in debt and debt-to-equity reduces balance-sheet flexibility and raises interest expense risk. Higher leverage can constrain the firm’s ability to pursue opportunistic acquisitions or absorb operational shocks, increasing financing vulnerability over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Sustained Revenue Growth
Multi-year top-line expansion from ~0.8B to ~2.1B demonstrates durable commercial scaling across subsidiaries. Persistent revenue growth supports operational leverage, broadens product/customer reach in healthcare niches, and enhances the company’s capacity to fund reinvestment and value-creating M&A.
Read all positive factors
MedCap AB (MCAP) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr7.16B
Dividend YieldN/A
Average Volume (3M)21.82K
Price to Earnings (P/E)31.9
Beta (1Y)0.63
Revenue Growth11.30%
EPS Growth-14.49%
CountrySE
Employees570
SectorHealthcare
Sector Strength45
IndustryAsset Management
Share Statistics
EPS (TTM)4.79
Shares Outstanding15,077,583
10 Day Avg. Volume14,106
30 Day Avg. Volume21,821
Financial Highlights & Ratios
PEG Ratio7.70
Price to Book (P/B)5.67
Price to Sales (P/S)3.90
P/FCF Ratio29.33
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)22.37
Revenue Forecast (FY)kr2.30B
MedCap AB Business Overview & Revenue Model
Company Description
MedCap AB (publ) is a private equity firm specializing in investments in secondary direct, later stage, industry consolidation, growth capital, middle market, mature, turnarounds, buyout. It prefers to invest in healthcare equipment and services, ...
How the Company Makes Money
MedCap makes money primarily through its consolidated operating subsidiaries rather than through financial trading. The core revenue model is based on: (1) Operating revenue from subsidiaries: The group’s subsidiaries sell their own products and s...
MedCap AB Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
72
Positive
Cash Flow
70
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 2.11B | 1.81B | 1.59B | 1.11B | 916.30M |
| Gross Profit | 321.00M | 1.06B | 926.40M | 462.40M | 369.80M |
| EBITDA | 473.90M | 396.00M | 341.90M | 237.30M | 191.50M |
| Net Income | 219.80M | 207.40M | 172.20M | 117.60M | 96.50M |
Balance Sheet | |||||
| Total Assets | 2.61B | 1.99B | 1.66B | 1.43B | 1.17B |
| Cash, Cash Equivalents and Short-Term Investments | 370.40M | 370.10M | 188.20M | 236.20M | 139.70M |
| Total Debt | 707.00M | 358.00M | 261.20M | 340.00M | 256.90M |
| Total Liabilities | 1.15B | 703.20M | 635.10M | 570.60M | 471.80M |
| Stockholders Equity | 1.45B | 1.28B | 1.02B | 856.30M | 696.00M |
Cash Flow | |||||
| Free Cash Flow | 280.50M | 293.80M | 188.70M | 41.20M | 55.40M |
| Operating Cash Flow | 342.70M | 360.00M | 228.00M | 85.50M | 116.30M |
| Investing Cash Flow | -391.30M | -128.80M | -152.30M | -56.10M | -64.80M |
| Financing Cash Flow | 52.20M | -46.10M | -119.70M | 61.20M | -64.10M |
MedCap AB Technical Analysis
Neutral
533.00
Price Trends
483.76
Negative
510.86
Negative
545.70
Negative
Market Momentum
-4.09
Negative
49.67
Neutral
82.68
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:MCAP, the sentiment is Neutral. The current price of 533 is above the 20-day moving average (MA) of 472.77, above the 50-day MA of 483.76, and below the 200-day MA of 545.70, indicating a neutral trend. The MACD of -4.09 indicates Negative momentum. The RSI at 49.67 is Neutral, neither overbought nor oversold. The STOCH value of 82.68 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SE:MCAP.
MedCap AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | kr6.82B | 6.12 | ― | 6.23% | -0.22% | -58.80% | |
64 Neutral | kr7.16B | 31.86 | 15.16% | ― | 11.30% | -14.49% | |
63 Neutral | kr9.23B | 8.37 | 11.24% | 2.18% | 4.72% | -38.28% | |
55 Neutral | kr5.07B | -3.58 | 7.55% | 0.79% | -25.75% | -27.25% | |
53 Neutral | kr16.03B | -3.91 | -23.18% | 1.13% | 22.38% | -153.85% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | kr4.15B | -9.33 | -1.58% | ― | 45733.33% | -105.08% |
* Healthcare Sector Average
SE:MCAP
MedCap AB
475.00
136.50
40.32%
SE:CRED.A
Creades AB
67.95
3.62
5.63%
SE:BURE
Bure Equity AB
216.20
-58.78
-21.38%
SE:LINC
Linc AB
71.70
10.50
17.16%
SE:SVOL.B
Svolder AB Class B
47.66
0.48
1.01%
SE:ORES
Investment AB Oresund
150.00
49.14
48.72%
MedCap AB Corporate Events
MedCap Delivers Strong Q4 and Full-Year 2025 Growth With Sharply Higher Margins
Feb 6, 2026
MedCap AB reported strong growth for the fourth quarter of 2025, with net sales up 25% to SEK 591.0 million and EBITA rising 73% to SEK 122.1 million, lifting the EBITA margin to 20.7%. On an adjusted basis, EBITA grew 68% and the margin improved ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.